Informações de Neumora Therapeutics Inc

Mais detalhes de Neumora Therapeutics Inc Empresa

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.



Código da empresaNMRA

Nome da EmpresaNeumora Therapeutics Inc

Data de listagemSep 15, 2023

CEOMr. Paul L. Berns

Número de funcionários110

Tipo de títulosOrdinary Share

Fim do ano fiscalSep 15

Endereço490 Arsenal Way

CidadeWATERTOWN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal02472

Telefone18577600900

Sitehttps://neumoratx.com/

Código da empresaNMRA

Data de listagemSep 15, 2023

CEOMr. Paul L. Berns

Executivos da empresa Neumora Therapeutics Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Paul L. Berns

Chairman of the Board, Chief Executive Officer, Co-Founder

7.68M

+3.27%

Dr. Daljit Singh (Bill) Aurora, Pharm.D.

Chief Operating and Development Officer

130.51K

+46.75%

Ms. Kristina M. Burow

Independent Director

47.72K

+72.78%

Mr. Michael Lee Milligan

Chief Financial Officer, Principal Accounting Officer

22.47K

-8.09%

Dr. Joshua Pinto, Ph.D.

President

--

Mr. Matthew K. (Matt) Fust

Independent Director

--

Mr. Jason G. Duncan

Chief Legal and Administrative Officer

--

Dr. Maykin Ho, Ph.D.

Independent Director

--

-100.00%

Mr. David Piacquad

Independent Director

--

Mr. Alaa A. Halawa

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Paul L. Berns

Chairman of the Board, Chief Executive Officer, Co-Founder

7.68M

+3.27%

Dr. Daljit Singh (Bill) Aurora, Pharm.D.

Chief Operating and Development Officer

130.51K

+46.75%

Ms. Kristina M. Burow

Independent Director

47.72K

+72.78%

Mr. Michael Lee Milligan

Chief Financial Officer, Principal Accounting Officer

22.47K

-8.09%

Dr. Joshua Pinto, Ph.D.

President

--

Mr. Matthew K. (Matt) Fust

Independent Director

--

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: qui, 2 de out

Investidores

Tipos de investidores

Investidores

Proporção

Amgen Inc

21.84%

ARCH Venture Partners

20.90%

Berns (Paul L)

4.74%

SB Global Advisers Ltd

4.04%

Invus Public Equities Advisors, LLC

2.69%

Outro

45.79%

Investidores

Proporção

Amgen Inc

21.84%

ARCH Venture Partners

20.90%

Berns (Paul L)

4.74%

SB Global Advisers Ltd

4.04%

Invus Public Equities Advisors, LLC

2.69%

Outro

45.79%

Tipos de investidores

Investidores

Proporção

Venture Capital

22.04%

Corporation

21.84%

Investment Advisor

21.62%

Individual Investor

5.65%

Hedge Fund

5.33%

Investment Advisor/Hedge Fund

3.10%

Endowment Fund

2.04%

Research Firm

0.70%

Family Office

0.05%

Outro

17.61%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

293

86.79M

53.64%

-40.47M

2025Q2

288

142.02M

87.70%

-25.57M

2025Q1

283

144.00M

90.43%

+12.16M

2024Q4

249

161.18M

99.54%

+45.20M

2024Q3

201

148.65M

93.66%

+40.67M

2024Q2

179

142.61M

90.03%

+47.65M

2024Q1

154

133.89M

85.01%

+50.39M

2023Q4

108

122.49M

78.90%

+50.97M

2023Q3

54

110.63M

71.42%

+110.63M

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Amgen Inc

35.37M

21.84%

--

Apr 10, 2025

ARCH Venture Partners

31.93M

19.72%

--

Nov 12, 2024

Berns (Paul L)

7.68M

4.74%

+242.77K

+3.27%

Apr 10, 2025

SB Global Advisers Ltd

6.54M

4.04%

--

Jun 30, 2025

Invus Public Equities Advisors, LLC

4.36M

2.69%

--

Jun 30, 2025

The Vanguard Group, Inc.

4.76M

2.94%

-562.13K

-10.56%

Jun 30, 2025

Fidelity Management & Research Company LLC

3.50M

2.16%

+6.35K

+0.18%

Jun 30, 2025

Wellcome Trust

3.31M

2.04%

--

Jun 30, 2025

ICONIQ Capital, LLC

2.56M

1.58%

--

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.55M

1.58%

-3.09M

-54.78%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

ProShares Ultra Nasdaq Biotechnology

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

iShares Biotechnology ETF

0.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0%

Schwab U.S. Small-Cap ETF

0%

iShares US Small-Cap Equity Factor ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

0%

Fidelity MSCI Health Care Index ETF

0%

Schwab U.S. Broad Market ETF

0%

Ver Mais

ProShares Ultra Nasdaq Biotechnology

Proporção0.03%

Invesco Nasdaq Biotechnology ETF

Proporção0.03%

Invesco RAFI US 1500 Small-Mid ETF

Proporção0.01%

iShares Biotechnology ETF

Proporção0.01%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporção0%

Schwab U.S. Small-Cap ETF

Proporção0%

iShares US Small-Cap Equity Factor ETF

Proporção0%

Virtus LifeSci Biotech Clinical Trials ETF

Proporção0%

Fidelity MSCI Health Care Index ETF

Proporção0%

Schwab U.S. Broad Market ETF

Proporção0%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados